Respi

RESPI is a startup addressing chronic respiratory disease through personalized medication that is based on constant user measurement and AI to predict user behavior. It was first conceived in 2014 and is currently in 80% far from a sellable MVP. It has achieved 2 conference publications, owns the IP in numerable prototypes and has 2 pending patents.
Chronic Pulmonary Disease affect millions and is currently the 3rd most severe cause of death. Despite this prevalence, there is no standardized system for self-management of pulmonary health and patients often mis-medicate leading to symptom aggravation, unnecessary hospitalization and even premature death. The absence of in situ monitoring, prohibits physicians to practically optimize dosage and medication type, adding a huge burden to both patients’ pulmonary health and the economy of healthcare systems.
RESPI offers a personalized management system for chronic respiratory disease. In its core, it consists of a smartphone enabled spirometer and a connected interpretive mobile application offering customized disease monitoring and coaching. The system is planned to be enriched with data from a connected air quality sensor and a smart medication inhaler.
With RESPI, patients have access to quantified data in order to medicate appropriately in times of distress, know if the medication has been effective and adhere to their medication scheme, while physicians can support personalized medication decisions.
Competition is trying to unlock the secret to patients. While offering a new “smart solution” can be conceptually easy, it is not easy to convince potential users and physicians to abandon the status quo.
Understanding the personality profile and the disease profile, as opposed to mass grouping patients based on spirometry results, while addressing physician needs is the key to making patients happy and much of RESPI research has gone towards deciphering these behaviors. Patients opt for ease of use and physicians opt for big understanding as opposed to big data, while utilizing existing protocols and medications that have been thoroughly tested for decades. Respi is focusing exactly on overcoming these hurdles.